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Cinaciguat prevents the 
development of pathologic 
hypertrophy in a rat model of left 
ventricular pressure overload
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Tamás Radovits1,*
Pathologic myocardial hypertrophy develops when the heart is chronically pressure-overloaded. 
Elevated intracellular cGMP-levels have been reported to prevent the development of pathologic 
myocardial hypertrophy, therefore we investigated the effects of chronic activation of the cGMP 
producing enzyme, soluble guanylate cyclase by Cinaciguat in a rat model of pressure overload-induced 
cardiac hypertrophy. Abdominal aortic banding (AAB) was used to evoke pressure overload-induced 
cardiac hypertrophy in male Wistar rats. Sham operated animals served as controls. Experimental 
and control groups were treated with 10 mg/kg/day Cinaciguat (Cin) or placebo (Co) p.o. for six weeks, 
respectively. Pathologic myocardial hypertrophy was present in the AABCo group following 6 weeks of 
pressure overload of the heart, evidenced by increased relative heart weight, average cardiomyocyte 
diameter, collagen content and apoptosis. Cinaciguat did not significantly alter blood pressure, but 
effectively attenuated all features of pathologic myocardial hypertrophy, and normalized functional 
changes, such as the increase in contractility following AAB. Our results demonstrate that chronic 
enhancement of cGMP signalling by pharmacological activation of sGC might be a novel therapeutic 
approach in the prevention of pathologic myocardial hypertrophy.
Long term presence of pathologic myocardial hypertrophy is a major underlying cause of heart failure (HF). One 
of its main inducing factors is pressure overload of the left ventricle (LV), which causes concentric LV hypertrophy 
(LVH) with collagen accumulation and subsequent impairment of diastolic function. This adverse remodelling 
of the LV can result in HF with preserved ejection fraction (HFpEF), a condition that is increasingly investigated, 
as it equals HF with reduced ejection fraction (HFrEF) both in outcomes and numbers1. The bulk of patients who 
develop HFpEF suffer from persistent hypertension2. It is well known that hypertensive heart disease (HHD) is 
initially characterized by compensated concentric LVH, which, eventually, transits to overt HF. Although effec-
tive pharmacological and device therapies have been developed to decrease the burden of HFrEF3, clinical trials 
targeting patients with HFpEF had neutral results to this date1,3. Therefore, new therapeutic approaches might be 
feasible in addressing the growing public health burden of HFpEF.
Cyclic GMP (cGMP) is an important regulator of many physiological and pathophysiological processes in 
the cardiovascular system, including cardiac remodelling4. Under physiological conditions, the major source of 
cGMP in cardiomyocytes is soluble guanylate cyclase (sGC), which is activated by nitric oxide (NO)5. The main 
effector of cGMP inside the cardiomyocyte is the cGMP-dependent protein kinase (PKG), which was identified as 
a key negative regulator of LVH and adverse remodelling6,7. Various cardiovascular diseases result in an impaired 
signalling through the NO-cGMP-PKG pathway8. It has previously been shown that elevated cytosolic levels of 
cGMP originated either from blockade of its degrading enzyme, phosphodiesterase type 5 (PDE-5)9 or from 
increasing its production by stimulating or activating sGC10,11 preserved myocardial structure and function in 
1Heart and Vascular Center, Semmelweis University, Városmajor u. 68., 1122 Budapest, Hungary. 2Institute of 
Pathophysiology, Semmelweis University, Nagyvárad tér 4., 1089 Budapest, Hungary. 3Department of Cardiac 
Surgery, University of Heidelberg, Im Neuenheimer Feld 110., 69210 Heidelberg, Germany. *These authors 
contributed equally to this work. Correspondence and requests for materials should be addressed to T.R. (email: 
radovitstamas@yahoo.com)
Received: 06 June 2016
accepted: 25 October 2016
Published: 17 November 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:37166 | DOI: 10.1038/srep37166
experimental ischemia-reperfusion models. Therefore, elevating myocardial cGMP levels might prove to be an 
effective new approach of preventing the development of pathologic LVH.
A new group of drugs named sGC activators has been developed12 in order to counteract the impairment of 
the NO-cGMP-PKG pathway. Cinaciguat (BAY 58-2667) is the firstly characterized and most potent member 
of the sGC activators13. It can activate sGC independently of its haem moiety, which serves as the physiologi-
cal NO sensor in sGC13. Under pathologic conditions associated with increased nitro-oxidative stress (such as 
diabetes, ischaemia/reperfusion or LVH8), the haem of sGC becomes oxidized, which renders it incapable of 
binding NO and facilitates its dissociation from the enzyme14, resulting in the inability of sGC to generate cGMP. 
Cinaciguat activates these inactive forms of sGC more potently than it does the reduced sGC14. This potentially 
disease-selective mode of action makes activators of sGC especially tempting new tools in our pharmacological 
therapeutic inventory.
In our present study, we aimed at characterizing the cardiac effects of Cinaciguat in a rat model of pressure 
overload-induced LVH. We used abdominal aortic banding (AAB) to induce pressure overload in our animals, 
which is a well-established and widely used procedure to evoke hypertension and pathologic LVH in rodents15–17.
Results
Echocardiography. The echocardiographic measurement performed on the 3rd postoperative week verified 
significantly elevated LV wall thickness values, relative wall thickness (RWT) and estimated LV mass (LVM) in 
the AABCo group compared to ShamCo without significant changes in chamber dimensions (Table 1). LVH 
increased over the second half of the treatment period in the AABCo animals (Table 1, Fig. 1), which was accom-
panied by significantly elevated LV end-systolic (LVESD) diameter compared to ShamCo. The Cinaciguat treat-
ment in aortic banded rats resulted in significantly decreased LV diastolic wall thicknesses, LVM and LVM index 
(LVMi) compared to AABCo at both time points (Table 1). Systolic posterior wall thickness at the 6th week of the 
treatment was also significantly decreased in the AABCin animals compared to the AABCo group, while ejection 
fraction (EF) and fractional shortening (FS) remained unchanged during the whole study (Table 1).
Body and organ weights. There was no significant difference among the groups in body weight 
(Supplementary Table 3). Heart weight normalized to tibial length (HW/TL) was significantly higher in the 
AABCo rats than in the ShamCo or ShamCin animals (Supplementary Table 3, 29.3 ± 0.8 mg/mm ShamCo, 
28.1 ± 0.9 mg/mm ShamCin vs. 38.4 ± 1.5 mg/mm AABCo, p < 0.05). HW/TL was significantly reduced in the 
AABCin animals compared to the AABCo rats (33.5 ± 0.7 mg/mm AABCin, p < 0.05). Relative wet lung (LuW/
TL) weight was significantly increased in the AABCo group compared to ShamCo. This parameter did not differ 
from ShamCo in the AABCin animals (Supplementary Table 3).
Hemodynamic measurements. Basic hemodynamic parameters, such as heart rate (HR), EF, stroke vol-
ume (SV), cardiac output (CO), or LV end-systolic volume (LVESV), and also parameters of preload, such as 
LV end-diastolic volume (LVEDV) and -pressure (LVEDP) were not significantly different among the groups 
(Table 2).
LV systolic (LVESP) and mean arterial blood pressure (MAP) proximal to the site of stenosis were significantly 
higher in both AAB groups than in the Sham groups, and neither of these parameters were affected by Cinaciguat 
(Table 2).
Maximum rate of LV pressure increment (dP/dtmax) was significantly higher in AABCo animals than in 
ShamCo rats (Table 2). Load independent indices of contractility, such as end-systolic elastance (Ees) and preload 
recruitable stroke work (PRSW) (Fig. 2), also showed that AABCo animals had significantly elevated LV con-
tractility compared to ShamCo. These parameters, however, indicated a significant decrease of contractility in 
3rd week 6th week
ShamCo ShamCin AABCo AABCin pband ptreat pint ShamCo ShamCin AABCo AABCin pband ptreat pint
AWTd (mm) 1.92 ± 0.04 1.85 ± 0.02 2.27 ± 0.05* 2.04 ± 0.05*# <0.0001 0.021 0.029 2.03 ± 0.02 1.97 ± 0.02& 2.40 ± 0.04*& 2.21 ± 0.03*#& <0.0001 0.0004 0.010
AWTs (mm) 2.87 ± 0.09 3.00 ± 0.03 3.39 ± 0.08* 3.20 ± 0.05 <0.0001 0.841 0.024 3.09 ± 0.08 3.11 ± 0.04 3.49 ± 0.07* 3.33 ± 0.06* <0.0001 0.852 0.027
PWTd (mm) 1.78 ± 0.04 1.78 ± 0.04 2.15 ± 0.05* 1.89 ± 0.06# <0.0001 0.041 0.004 1.85 ± 0.03 1.72 ± 0.03 2.32 ± 0.04*& 2.05 ± 0.07*#& <0.0001 0.001 0.112
PWTs (mm) 2.87 ± 0.12 2.94 ± 0.07 3.16 ± 0.09* 2.97 ± 0.04 0.016 0.832 0.034 2.80 ± 0.05 2.80 ± 0.04 3.29 ±  0.07* 3.03 ± 0.07*# <0.0001 0.127 0.014
LVEDD (mm) 6.43 ± 0.08 6.35 ±  0.09 6.78 ± 0.18 6.54 ± 0.12 0.066 0.234 0.537 6.54 ± 0.11 6.65 ± 0.13 7.04 ± 0.15 6.48 ± 0.18# 0.122 0.087 0.049
LVESD (mm) 3.59 ±  0.08 3.30 ± 0.05 3.92 ±  0.20 3.60 ± 0.10 0.021 0.050 0.898 3.56 ± 0.12 3.52 ± 0.12& 4.19 ± 0.14*& 3.74 ± 0.12 0.002 0.064 0.159
RWT (%) 0.58 ± 0.01 0.57 ± 0.01 0.66 ±  0.02* 0.60 ± 0.02 0.034 0.130 0.093 0.59 ± 0.01 0.56 ± 0.02 0.67 ± 0.02* 0.64 ± 0.01* <0.0001 0.076 0.759
LVM (g) 0.81 ± 0.03 0.76 ± 0.01 1.15 ± 0.06* 0.90 ± 0.04# <0.0001 0.003 0.020 0.88 ± 0.03& 0.85 ± 0.02& 1.33 ± 0.05*& 1.00 ± 0.04#& <0.0001 <0.0001 0.001
LVMi (mg/g) 2.35 ± 0.06 2.35 ± 0.03 3.38 ± 0.14* 2.90 ± 0.12*# <0.0001 0.058 0.023 2.09 ± 0.05& 2.05 ± 0.05& 3.15 ± 0.09* 2.57 ± 0.06*#& <0.0001 0.0002 0.001
FS (%) 44 ± 2 47 ± 1 42 ± 1 44 ± 1 0.180 0.061 0.518 44 ± 1 46 ± 1 41 ± 1 43 ± 1 0.009 0.128 0.821
EF (%) 62 ± 2 66 ± 1 62 ± 1 69 ± 2*# 0.310 0.002 0.339 66 ± 2 69 ± 1 62 ± 1* 69 ± 2# 0.232 0.013 0.339
Table 1.  Echocardiographic measurements. Indexes: d: diastole, s: systole; AWT: anterior wall thickness, 
PWT: posterior wall thickness; LVEDD: left ventricular end diastolic diameter, LVESD: left ventricular end 
systolic diameter; RWT: relative wall thickness; LVM: left ventricular mass, LVMi: left ventricular mass index; 
FS: fractional shortening; EF: ejection fraction; pband: p value of ‘aortic banding’ main effect; ptreat: p value of 
‘Cinaciguat treatment’ main effect; pint: interaction p value *p< 0.05 vs. ShamCo; #p < 0.05 vs. AABCo; &p < 0.05 
vs. 3rd week.
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AABCin compared to AABCo rats. dP/dtmax-end-diastolic volume relationship (dP/dtmax-EDV) had a similar 
trend (Fig. 2).
Figure 1. Representative echocardiographic images from the 6th week in diastole. White bars represent 
walls, and red bars show cavities. Note the difference among groups in the length of the bars.
ShamCo ShamCin AABCo AABCin pband ptreat pint
HR (1/min) 433 ± 15 412 ± 17 435 ± 11 444 ± 17 0.255 0.679 0.309
MAP (mmHg) 134 ± 5 127 ± 5 183 ± 7* 177 ± 5* <0.0001 0.218 0.902
ESV (μ l) 103 ± 8 91 ± 8 97 ± 7 96 ± 8 0.959 0.400 0.436
EDV (μ l) 221 ± 19 190 ± 13 233 ± 11 199 ± 16 0.790 0.094 0.728
LVESP (mmHg) 140 ± 4 138 ± 3 191 ± 14* 185 ± 6* <0.0001 0.610 0.903
LVEDP (mmHg) 4.7 ± 0.5 4.1 ± 0.4 4.5 ± 0.3 4.9 ± 0.6 0.248 0.741 0.484
SV (μ l) 145 ± 14 128 ± 7 156 ± 10 135 ± 7 0.390 0.066 0.857
EF (%) 60 ± 1 61 ± 2 61 ± 1 61 ± 1 0.489 0.685 0.854
CO (ml/min) 63.3 ± 6.7 52.4 ± 3.1 67.6 ± 4.6 56.5 ± 1.8 0.373 0.025 0.984
SW (mmHg*μ l) 16.49 ± 1.76 14.29 ± 1.19 20.92 ± 1.64 17.67 ± 1.40 0.017 0.088 0.736
Ea (mmHg/μ l) 1.03 ± 0.10 1.06 ± 0.07 1.28 ± 0.13 1.39 ± 0.07 0.008 0.479 0.668
τ G (ms) 11.21 ± 0.49 11.33 ± 0.75 16.30 ± 1.65* 13.65 ± 0.66 0.001 0.225 0.185
dP/dtmax (mmHg/s) 8589 ± 460 8200 ± 543 10999 ± 430* 10374 ± 648 0.0001 0.338 0.822
Table 2.  Baseline hemodynamic parameters. HR: heart rate; ESV: end-systolic volume, EDV: end diastolic 
volume; LVSP: left ventricular systolic pressure, LVEDP: left ventricular end diastolic pressure; MAP: mean 
arterial pressure; SV: stroke volume; EF: ejection fraction; CO: cardiac output; SW: stroke work; Ea: arterial 
elastance; τG: time constant of active relaxation according to Glantz (tau); dP/dtmax: maximum rate of pressure 
change; pband: p value of ‘aortic banding’ main effect; ptreat: p value of ‘Cinaciguat treatment’ main effect; pint: 
interaction p value *p < 0.05 vs. ShamCo; #p < 0.05 vs. AABCo.
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Active relaxation was impaired in the AABCo rats compared to ShamCo, as evidenced by the time constant of 
LV pressure decay (τ ), while it was similar to ShamCo in the AABCin animals (Table 2).
Histology, immunohistochemistry, biochemistry. Morphological changes were present on the micro-
scopic level as well. Average cardiomyocyte width was significantly increased in the AABCo group compared to 
ShamCo (Fig. 3a and e), which was significantly lower in AABCin rats than in AABCo animals. Quantitative 
analysis of heart sections stained with Picrosirius red showed that the collagen area of subendocardial LV myocar-
dium was significantly increased in the AABCo group compared to ShamCo, which was significantly decreased 
in the AABCin rats compared to AABCo (Fig. 3b and f). Terminal deoxynucleotidyl transferase dUTP nick end 
labelling (TUNEL) revealed a significant increase in the number of apoptotic cell nuclei in the AABCo group 
compared to ShamCo and AABCin (Fig. 3c and g).
Analysing immunohistochemical staining on myocardial sections for cGMP resulted in significantly higher 
score in AABCin rats than either in ShamCo or AABCo animals (Fig. 3d and h). Plasma level of cGMP was also 
significantly elevated in the AABCin animals compared to both ShamCo and AABCo groups (Fig. 4).
mRNA analysis. Pressure overload of the left ventricle resulted in elevated myocardial expression of atrial 
natriuretic peptide (ANP) and endothelial NO synthase (NOS3) (Fig. 5a), and decreased ratio of myosin heavy 
chain isoforms α and β (MHCα /MHCβ ) expression (Fig. 5a), indicating the reactivation of the foetal gene pro-
gram in the AABCo animals. The Cinaciguat treatment normalised the relative expression of NOS3 and the 
ratio of MHCα /MHCβ expression (Fig. 5a), while ANP expression was unaltered by the treatment (Fig. 5a). 
Expression ratio of sarco/endoplasmic reticulum Ca2+-ATPase 2a (SERCA2a) and phospholamban (Pln) was 
significantly elevated in the AABCin rats (Fig. 5a).
Anti-apoptotic signalling was reinforced by Cinaciguat, as evidenced by the significant increase in B-cell lym-
phoma 2 (Bcl-2) expression and the strong tendency towards higher expression of 70 kDa heat shock protein 
(HSP70) in the AABCin animals (Fig. 5b).
Immunoblot analysis. Protein density of protein kinase G (PKG) was significantly elevated in myocardial 
homogenates of AABCo rats, while it was comparable to ShamCo in the AABCin group (Fig. 4). Phosphorylation 
Figure 2. Cinaciguat normalises increased contractility in pressure overload. Baseline characteristics of 
pressure-volume relations did not differ in the AABCo and AABCin groups (a). P-V loops recorded during 
occlusion of the inferior caval vein (b) and the load independent indices of contractility derived from these 
measurements (c) show, however, that Cinaciguat significantly decreased the increase in contractility following 
abdominal aortic banding. PRSW: preload recruitable stroke work; Ees: end systolic elastance; dP/dtmax-EDV: 
maximum rate of pressure change – end diastolic volume relationship; pint: interaction p value *p < 0.05 vs. 
ShamCo; #p < 0.05 vs. AABCo.
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ratio of vasodilator-stimulated phosphoprotein (VASP) and Pln are widely used indicators of PKG activity, both 
of which were elevated following the Cinaciguat treatment (Fig. 4).
Discussion
In our current work we demonstrate for the first time that the chronic activation of sGC by Cinaciguat and the 
subsequent rise in cGMP levels efficiently reduce pressure overload-induced pathologic myocardial hypertrophy 
in vivo despite the unchanged loading of the LV. In parallel with the significant morphological changes, functional 
alterations were normalised by the Cinaciguat treatment following AAB.
In vivo, the major drive in the background of the hypertrophic response of cardiomyocytes to chronically 
increased afterload is the stretching of the cell membrane18,19. Recently published in vitro studies have shown that 
Cinaciguat has anti-hypertrophic effects in cultured neonatal rat cardiomyocytes20, suggesting that the chronic 
activation of the NO-cGMP-PKG pathway is capable of decreasing cardiomyocyte hypertrophy irrespective of 
Figure 3. Histological alterations in pressure overload are blunted by Cinaciguat. Differences between the 
groups are illustrated in representative photomicrographs of left ventricular (LV) myocardial sections with 
haematoxylin-eosin (a) and Picrosirius red staining (b), TUNEL (c) and cGMP immunohistochemistry (d). 
Average cardiomyocyte diameter (e) and collagen area of subendocardial LV myocardium (f) was significantly 
elevated in the AABCo group compared to ShamCo, both of which alterations were significantly decreased 
following Cinaciguat treatment. TUNEL staining revealed a significant increase in the number of apoptotic cell 
nuclei in the AABCo group compared to ShamCo and AABCin (g). cGMP score (h) was significantly higher 
in the AABCin group than in the AABCo animals. pint: interaction p value *p < 0.05 vs. ShamCo; #p < 0.05 vs. 
AABCo.
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the mechanical stress inflicted on cardiomyocytes by hemodynamic load. The significance of NO-cGMP-PKG 
signalling might be that it regulates a plethora of important mechanisms including Ca2+-related signalling path-
ways, troponin I21 and various ion channel phosphorylation22. Our present results are in line with the above 
mentioned anti-hypertrophic properties of sGC-activation. Furthermore, in vivo myocardial anti-hypertrophic 
effect of Cinaciguat in previously published works was suggested to be secondary to the amelioration of the 
primary disease (pulmonary hypertension23 and uraemia24) by the drug. In contrast, the primary disease in our 
model cannot be resolved by the drug, therefore we show here for the first time that Cinaciguat exerts a primary 
anti-hypertrophic effect in vivo. This effect is present irrespective of the hemodynamic loading of the LV, which 
might be the result of the increased activity of PKG due to the elevation of intracellular cGMP level by Cinaciguat. 
This is evidenced by myocardial and plasma cGMP-levels (Figs 3d,h and 4), and increased phosphorylation ratio 
of VASP and Pln (Fig. 4), both of which are widely used as markers of PKG activity25,26.
Although oxidation and thus inactivation of sGC has been reported in the development of LVH27, plasma 
cGMP levels were found to be unaltered in the AABCo group when compared to ShamCo. This finding might be 
explained by the overexpression of natriuretic peptides (such as ANP, Fig. 5a) and subsequent cGMP-production 
by particulate GC28, which could be interpreted as an ineffective compensatory reaction to sGC inactivation. 
Furthermore, pGC might not be able to directly replace the function of sGC in the cell; the different subcellular 
compartmentalisation of sGC versus pGC derived cGMP should be taken into account29.
A significant concentric LVH was present in the AABCo group by the 6th week, as evidenced by RWT values. 
AWTd, PWTd and LVEDD were significantly decreased in the AABCin group compared to AABCo (Table 1). 
Indeed, LVMi estimated from our echocardiographic measurements showed that Cinaciguat significantly 
decreased the extent of LVH (Table 1). Our finding correlates with previous data about the PDE-5 inhibitor silde-
nafil, which also increases the amount of intracellular cGMP, and was shown to reduce LVH significantly9. Post 
mortem organ weight measurements correlated with these results: AABCo rats developed a significant increase 
both in absolute and relative heart weight compared to ShamCo, which is similar to previous data in this model30. 
This gain of heart weight was significantly decreased by the Cinaciguat treatment (Supplementary Table 3), which 
clearly reflects the anti-hypertrophic properties of Cinaciguat.
Chronically increased afterload induces compensatory remodelling of the myocardium. Unlike physiological 
myocardial hypertrophy that occurs in athletes, pathologic stimuli such as hypertension lead to maladaptive 
changes in the cellular structure of cardiomyocytes31. On the microscopic level, we found a significant increase 
in average cardiomyocyte width and subendocardial collagen area in the AABCo group compared to ShamCo 
(Fig. 3a,b,e and f). Treatment with Cinaciguat significantly reduced both average cardiomyocyte width and sub-
endocardial collagen area in our aortic banded rats (Fig. 3a,b,e and f), which correlates well with the decrease 
observed in LVMi and heart weight (Table 1 and Supplementary Table 3) both in this study and with previous 
results9,32.
Figure 4. Effects of Cinaciguat on cGMP signalling in pressure overload. The strong sGC activating 
effect of Cinaciguat during pathologic conditions was confirmed by measuring plasma level of cGMP, which 
was significantly elevated in AABCin rats. cGMP activates PKG, which then phosphorylates VASP and Pln, 
phosphorylation ratio of which are widely used markers of PKG activity. Both of these were markedly increased 
despite the unchanged amount of PKG in the AABCin group, indicating increased PKG activity in these 
animals. Representative Western blot bands are shown for each group and investigated protein on the right. 
PKG: protein kinase G; Pln: phospholamban; VASP: vasodilator stimulated phosphoprotein; pint: interaction  
p value *p < 0.05 vs. ShamCo; #p < 0.05 vs. AABCo.
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A major change in the subcellular phenotype characteristic to pathologic LVH is the reactivation of the foe-
tal gene program33. Indeed, we observed a shift toward the expression of the less efficient, but less energy con-
suming β isoform of myosin heavy chain from the α isoform in the AABCo animals, a well-known change34 
that was completely normalised by the Cinaciguat treatment, as observed in the AABCin group (Fig. 5a). This 
result is remarkable in the light of the similar loading of the LV, as MAP was comparable in the aortic banding 
groups (Table 2). It must be noted here that Cinaciguat has been critically discussed in recent publications due 
to its hypotensive effect in human clinical trials, which utilized the drug intravenously35,36. It is very important 
to emphasize, however, that consistently with other pharmacological agents, the pharmacokinetics of Cinaciguat 
is significantly different when administered orally. In line with this, according to previous reports, a single oral 
dose of 10 mg/kg Cinaciguat only mildly and transiently lowers blood pressure13,37. Furthermore, chronic oral 
administration of the drug in this dose did not significantly alter arterial blood pressure in the systemic circu-
lation neither in murine models of pulmonary hypertension23 nor in a rat model of diabetic cardiomyopathy38. 
Similar results with oral Ataciguat and GSK2181236A, two further sGC activators have recently been reported 
in a rat myocardial infarction model and in spontaneously hypertensive stroke prone rats10,39. Conforming these 
data, we did not observe any changes in MAP of the rats in response to orally administered Cinaciguat at the time 
of the hemodynamic assessment, 24 h after the last application of the drug. Nevertheless, the observed robust 
overexpression of ANP in both AAB groups (Fig. 5a) provides evidence for unchanged loading, similar LV wall 
stretch and mechanical hypertrophic stimulus in the AABCo and AABCin animals.
Figure 5. Gene expression changes are prevented in response to Cinaciguat treatment. (a) Aortic banding 
resulted in the reactivation of the foetal gene program, as evidenced by the elevated expression of ANP, MHCβ ,  
and NOS3, the decreased expression of MHCα . Expression of NOS3 and MHCα along with the MHC isoform 
expression ratio was normalised by the Cinaciguat treatment following aortic banding. The SERCA2a/Pln 
expression ratio was significantly increased in the AABCin rats compared to the AABCo animals. (b) Both 
HSP70 and Bcl-2 expression was markedly elevated in the AABCin group, indicating reinforced anti-apoptotic 
signalling in these animals. ANP: atrial natriuretic peptide; Bcl-2: B-cell lymphoma 2; HSP70: 70 kDa heat 
shock protein; MHCα /β : α and β isoform of myosin heavy chain; NOS3: endothelial nitric oxide synthase; Pln: 
phospholamban; SERCA2a: sarcoplasmic and endoplasmic reticulum Ca2+ ATPase isoform 2a; pint: interaction 
p value *p < 0.05 vs. ShamCo; #p < 0.05 vs. AABCo.
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Excessive stretching of the plasma membrane of cardiac myocytes could also induce programmed cell death40. 
Our results correspond with previous data, we observed a significant increase in the number of apoptotic cell 
nuclei in the AABCo group compared to ShamCo with TUNEL staining (Fig. 3c and g). This alteration was 
normalised by the Cinaciguat treatment, which improvement could be explained by reinforced anti-apoptotic 
signalling, as evidenced by the increased expression of Bcl-2 and HSP70 (Fig. 5b).
Thus, we observed a significant improvement of the detrimental changes occurring during pathologic LVH 
on all three observable (i.e., macroscopic, microscopic and molecular) levels in response to Cinaciguat treatment.
As described above, chronic overload of the LV results in pathologic morphological changes of the myocar-
dium. These result in an initial, functionally compensated phase with hypertrophy and an increase in contractility, 
to compensate for the increased afterload. Eventually, however, decompensation with LV dilatation, systolic dys-
function and overt HF develops41. We found maintained systolic performance in our animals with echocardiog-
raphy both on the 3rd and 6th week (Table 1), which suggests that our AABCo and AABCin animals were in the 
compensated hypertrophic phase throughout the experiment. The significantly increased LVESD in the AABCo 
animals, however, might anticipate LV dilatation and systolic dysfunction, while Cinaciguat effectively prevented 
this alteration as well (Table 1).
Analysis of P-V data acquired during invasive hemodynamic measurements provides more precise assessment 
of cardiac performance. Ees (the slope of ESPVR) was proposed as a fairly load-insensitive index of ventricular 
contractility. PRSW (the slope of the linear relation between SW and EDV) has been described as a parameter 
independent of chamber size and mass, and it is sensitive to contractile function of the ventricle42. These indices 
showed an increase in LV contractility in the AABCo group, which was not present following the Cinaciguat 
treatment (Table 2 and Fig. 2). These results are partially explained by the anti-hypertrophic effects of Cinaciguat, 
as described above and in previous studies43,44. Further important contributors to these results might be func-
tional changes induced by the activation of PKG: inactivation of L-Type Ca2+-channels and activation of late 
rectifier K+-channels might both decrease intracellular Ca2+ concentration22. What is more, phosphorylation of 
troponin I by PKG could ameliorate Ca2+-sensitivity of cardiomyocytes21. Therefore, while not completely pre-
venting adaptive compensatory hypertrophy (Table 1, Fig. 3a and e, Supplementary Table 3), Cinaciguat appears 
to attenuate the excess in the hypertrophic response that might not be required for the LV to withstand increased 
afterload45, in parallel with ameliorating all characteristic changes of pathological hypertrophy including fibrosis 
(Fig. 3b and f), apoptosis (Fig. 3c and g) and reactivation of the foetal gene program (Fig. 5a).
A hallmark of HHD is the impairment of LV diastolic function long before systolic dysfunction occurs, result-
ing clinically in the HFpEF phenotype. Both the decrease of passive compliance and impaired active relaxation 
of the LV can be in the background of diastolic dysfunction46. Despite the elevated subendocardial collagen area 
in the AABCo animals (Fig. 3b and f), LVEDP did not change compared to ShamCo (Table 2), which suggests 
that passive compliance of the LV was unaltered at this early stage of HHD. Increased collagen area in the AABCo 
group was present only in the subendocardial region, which correlates with previous results32. Collagen depo-
sition, as observed by the same authors, expanded to the complete width of the LV wall when the duration of 
pressure overload was longer32. τ , on the other hand, which is the time constant of LV pressure decay and thus 
characterises active relaxation, was significantly increased in the AABCo group, suggesting impaired active relax-
ation (Table 2). There was no sign of diastolic dysfunction in the AABCin animals, which could be explained by 
the elevated ratio of expression of SERCA2a and Pln (Fig. 5a) and the increased phosphorylation ratio of Pln 
(Fig. 4) compared to AABCo. Both of these changes could contribute to facilitation of cytoplasmic Ca2+-clearance 
in the early phase of diastole, resulting in maintained active relaxation47,48.
Diastolic dysfunction causes backward failure initially in the pulmonary circulation49. In accordance with this, 
we found significantly elevated relative wet lung weight in our AABCo rats, while it was comparable to ShamCo 
in the AABCin animals (Supplementary Table 3).
Limitations. LV geometry and the amount of fibrotic components in the myocardial wall might both influ-
ence LV contractility parameters measureable by PV-analysis. Despite this method being the current gold stand-
ard for assessing different aspects of cardiac function, it is not possible to separate these confounding factors from 
the true contractility of the myocardial sarcomere in vivo. Therefore, the observed increase in contractility in the 
AABCo group and conversely, normalization of contractility in AABCin animals might partially be caused by the 
structural differences of the LV wall between these groups.
Conclusions
Our research group shows here for the first time that chronic activation of sGC by Cinaciguat prevents the devel-
opment of pathologic myocardial hypertrophy in vivo irrespective of hemodynamic load. We observed the bene-
ficial effect of sGC activation on morphological, functional and molecular levels as well. sGC activators therefore 
might prove to be an efficient new therapeutic approach in the treatment of pathologic myocardial hypertrophy.
Materials and Methods
For more details, see the online supplementary material. All animals received humane care in compliance with 
the “Principles of Laboratory Animal Care”, formulated by the National Society for Medical Research and the 
Guide for the Care and Use of Laboratory Animals, prepared by the Institute of Laboratory Animal Resources 
and published by the National Institutes of Health (NIH Publication No. 85-23, Revised 1996). All procedures 
and handling of the animals during the study were reviewed and approved by the Ethical Committee of Hungary 
for Animal Experimentation. Young adult (10 weeks old, body weight = 220–240 g) male Wistar rats (n = 35) 
(“Toxi-Coop” Zrt., Dunakeszi, Hungary) were housed in a room with constant temperature of 22 ± 2 °C with a 
12 h light-dark cycle, were fed a standard laboratory rat chow ad libitum and had free access to water.
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Abdominal aortic banding procedure. After acclimation, banding of the abdominal aorta (AAB, n = 19) 
between the renal arteries and the superior mesenteric artery, or sham operation (n = 16) was performed in 
pentobarbital sodium (60 mg/kg i.p.) anaesthesia as previously described16,50. After recovering from anaesthesia 
and on the first and second postoperative day, all animals received meloxicam (1.5 mg/kg p.o.) for postoperative 
analgesia.
Experimental groups, chronic treatment protocol. 5 days after the operations, sham and AAB animals 
were randomized into control or treatment groups (ShamCo, n = 8; ShamCin, n = 8; AABCo, n = 10; AABCin, 
n = 9). Treated animals received Cinaciguat (10 mg/kg p.o.) suspended in 0.5% methylcellulose solution via oral 
gavage, while control rats were given only the vehicle every day for 6 weeks. The dosage was adjusted to body 
weight, which was measured three times a week during the whole study period.
Echocardiography. We performed echocardiographic measurements at the 3rd and 6th week after the oper-
ations as previously described42. Briefly, two-dimensional and M-mode echocardiographic images of long- and 
short (mid-papillary level)-axis were recorded in pentobarbital sodium (60 mg/kg i.p.) anaesthetised animals 
using a 13-MHz linear transducer (GE 12L-RS, GE Healthcare, Waukesha, WI, USA) connected to an echocar-
diographic imaging unit (Vivid i, GE Healthcare). Digital images (Fig. 1) were analysed by an investigator in 
blinded fashion using an image analysis software (EchoPac, GE Healthcare). LV anterior wall thickness (AWT), 
posterior wall thickness (PWT), LVEDD and LVESD in diastole (index: d) and systole (index: s) were measured 
on two-dimensional recordings of the short-axis at the mid-papillary muscle level. All values were averaged over 
three consecutive cycles. The following parameters were derived from these measurements: FS, end-diastolic 
(LVEDV) and end-systolic (LVESV) LV volumes, SV, EF, and LVM. To calculate LVMi, we normalized the LVM 
values to the body weight of the animal.
Hemodynamic measurements: LV Pressure-Volume (P-V) analysis. P-V analysis was performed 
in each rat as previously described51. Briefly, rats were anesthetised with pentobarbital sodium (60 mg/kg i.p.), 
tracheotomised, intubated and ventilated. A polyethylene catheter was inserted into the left external jugular vein 
for fluid administration. A 2-Fr micro tip pressure-conductance catheter (SPR-838, Millar Instruments, Houston, 
TX, USA) was inserted into the right carotid artery and advanced into the ascending aorta, then the catheter was 
advanced into the LV under pressure control. LVESP and LVESV, LVEDP and LVEDV, dP/dtmax, τ (according to 
the Glantz method), EF and SW were computed and calculated using a special P-V analysis program (PVAN, 
Millar Instruments). SV and CO were calculated and corrected according to in vitro and in vivo volume cali-
brations using PVAN software. In addition to the above parameters, the slope (Ees) of the LV end-systolic P-V 
relationship (ESPVR; according to the parabolic curvilinear model52), PRSW, and dP/dtmax-EDV were calculated 
as load-independent indices of LV contractility. At the end of each experiment, 100 μ l of hypertonic saline was 
injected intravenously, and from the shift of P-V relations, parallel conductance volume was calculated by the 
software and used for the correction of the cardiac mass volume. The volume calibration of the conductance sys-
tem was performed as previously described42. After completion of the hemodynamic measurements all animals 
were euthanized by exsanguination.
Post mortem measurements. After euthanasia, the heart, the lung and the liver of the animals were 
immediately placed into cold saline and were measured on a scale. This was followed by the sampling of the 
organs, as described below. To exclude the natural variability between the weights of the animals, the right tibia of 
every rat was also prepared and its length measured53.
Histology and immunohistochemistry. Hearts were harvested immediately after euthanasia, and sam-
ples were placed in 4% buffered paraformaldehyde solution. 5 μ m thick heart sections were stained with hae-
matoxylin and eosin, Picrosirius red, immunohistochemical staining for cGMP, and terminal deoxynucleotidyl 
transferase dUTP nick end labelling (TUNEL) staining to detect DNA strand breaks in LV myocardium. Light 
microscopic examination was performed with a Zeiss microscope (Axio Observer.Z1, Carl Zeiss, Jena, Germany), 
and digital images were captured using an imaging software (QCapture Pro 6.0, QImaging, Surrey, BC, Canada).
The mean value of transverse transnuclear widths of 100 randomly selected, longitudinally oriented LV car-
diomyocytes represents each sample. The amount of myocardial collagen was determined by measuring the area 
fraction of the Picrosirius red-stained areas of five randomly selected visual fields (magnification: 200x) of sub-
endocardial LV myocardium of each section with ImageJ software. Immunohistochemical reactivity for cGMP 
was examined with light microscopy at a magnification of 400x. Semi-quantitative scoring (scores 0–4; 0: no 
staining, 1: weak, 2: mild, 3: strong, 4: very strong staining) was performed by two people blinded to the groups 
as described elsewhere54. TUNEL positive cell nuclei were counted by two blinded observers in 10 fields of each 
section at 200x magnification. Data were normalized to the mean value of the ShamCo group and were used to 
perform statistical analysis.
Biochemical measurements. After hemodynamic measurements were completed, blood samples from the 
inferior caval vein were collected in tubes rinsed with EDTA. The blood samples were centrifuged at 3,000 RPM 
for 15 min at 4 °C, then separated plasma was stored in aliquots at -80°C. Plasma level of cGMP was determined 
using an enzyme immunoassay kit as per manufacturer’s protocol (Amersham cGMP EIA Biotrak System, GE 
Healthcare, Little Chalfont, Buckinghamshire, UK).
Cardiac mRNA analysis. LV myocardial tissue samples were harvested immediately after euthanasia, 
snap frozen in liquid nitrogen, and stored at − 80 °C. LV tissue was homogenized in RLT buffer, and RNA was 
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isolated from the ventricular samples using the RNeasy Fibrous Tissue Mini Kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s instructions. Quantitative real-time PCR was performed with the StepOne-Plus 
Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) in triplicates of each sample for the following 
targets: α - and β -isoform of myosin heavy chain (MHCα , MHCβ ), endothelial nitric oxide synthase (NOS3), 
atrial natriuretic peptide (ANP), B cell lymphoma 2 (Bcl-2), 70 kDa heat shock protein (HSP70), sarcoplasmic 
and endoplasmic reticulum Ca2+-ATPase isoform 2a (SERCA2a) and phospholamban (Pln), all purchased 
from Applied Biosystems. Gene expression data were normalized to glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH), and expression levels were calculated using the CT comparative method (2−ΔCT). All results are 
expressed as values normalized to a positive calibrator (a pool of cDNAs from all samples of the ShamCo group).
Immunoblot analysis. Immunoblot analysis was performed as previously described55. Briefly, LV tissue 
samples were homogenized and were boiled with Laemmli buffer. Equal amounts of protein (30 μ g) were loaded 
and separated on commercially available precast 4–12% SDS-PAGE gels (NuPAGE® Novex® Bis-Tris Mini Gel, 
Invitrogen, Carlsbad, CA, USA). Afterwards, proteins were transferred to nitrocellulose membrane by using a 
semi-dry electroblotting system (iBlot™ Gel Transfer Device, Invitrogen). Membranes were incubated overnight 
at 4 °C with primary antibodies (all purchased from Cell Signaling, Danvers, MA, USA, unless noted otherwise) 
against various target proteins as follows: members of NO signalling such as protein kinase G (PKG, primary 
antibody from Enzo Life Sciences, Plymouth Meeting, PA, USA), vasodilator-stimulated phosphoprotein (VASP) 
and phospho-VASP, phospholamban (Pln) and phospho-Pln as markers of PKG activity. After washing, mem-
branes were incubated in horseradish peroxidase (HRP) – conjugated secondary antibody dilutions at room tem-
perature (RT) for 1 h (anti-rabbit IgG or anti-mouse IgG as appropriate, 1:2000). Immunoblots were developed 
using Pierce® ECL Western Blotting Substrate Kit (Thermo Scientific, Rockford, IL, USA). Protein band densities 
were quantified using GeneTools software (Syngene, Frederick, MD, USA). GAPDH (primary antibody from 
Millipore, Billerica, MA, USA) was used to assess equal protein loading. Values of protein band densities (after 
adjusting to GAPDH band densities) were normalized to the average value of the ShamCo group and were used 
to perform statistical analysis. Representative original immunoblots are shown in Supplementary Figure 1.
Drugs. All drugs listed were purchased from Sigma-Aldrich (St. Louis, MO, USA) except for Cinaciguat, 
which is a kind gift of Bayer AG (Wuppertal, Germany).
Statistical analysis. Statistical analysis was performed on a personal computer with a commercially availa-
ble software (GraphPad Prism 6, La Jolla, CA, USA).
All data are expressed as mean ± standard error of the mean (SEM). After testing normal distribution of 
the data using the Shapiro-Wilk test, two-factorial analysis of variance (ANOVA) (with ‘aortic banding’ and 
‘Cinaciguat treatment’ as factors) was carried out to detect independent effects of the factors (pband, ptreat) and 
significant banding × treatment interactions (pint). Tukey’s post hoc testing was performed to evaluate differences 
between the groups. Data that did not show normal distribution were transformed logarithmically before per-
forming two-factorial ANOVA.
A paired Student’s t-test was performed for comparing data of the echocardiographic measurements at 2 time 
points within a group. Differences were considered statistically significant when p < 0.05.
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